Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Neuropsychopharmacology ; 49(6): 924-932, 2024 May.
Article in English | MEDLINE | ID: mdl-38326458

ABSTRACT

The rewarding effects of stimulant drugs such as methylphenidate (MP) depend crucially on how fast they raise dopamine in the brain. Yet how the rate of drug-induced dopamine increases impacts brain network communication remains unresolved. We manipulated route of MP administration to generate fast versus slow dopamine increases. We hypothesized that fast versus slow dopamine increases would result in a differential pattern of global brain connectivity (GBC) in association with regional levels of dopamine D1 receptors, which are critical for drug reward. Twenty healthy adults received MP intravenously (0.5 mg/kg; fast dopamine increases) and orally (60 mg; slow dopamine increases) during simultaneous [11C]raclopride PET-fMRI scans (double-blind, placebo-controlled). We tested how GBC was temporally associated with slow and fast dopamine increases on a minute-to-minute basis. Connectivity patterns were strikingly different for slow versus fast dopamine increases, and whole-brain spatial patterns were negatively correlated with one another (rho = -0.54, pspin < 0.001). GBC showed "fast>slow" associations in dorsal prefrontal cortex, insula, posterior thalamus and brainstem, caudate and precuneus; and "slow>fast" associations in ventral striatum, orbitofrontal cortex, and frontopolar cortex (pFDR < 0.05). "Fast>slow" GBC patterns showed significant spatial correspondence with D1 receptor availability (estimated via normative maps of [11C]SCH23390 binding; rho = 0.22, pspin < 0.05). Further, hippocampal GBC to fast dopamine increases was significantly negatively correlated with self-reported 'high' ratings to intravenous MP across individuals (r(19) = -0.68, pbonferroni = 0.015). Different routes of MP administration produce divergent patterns of brain connectivity. Fast dopamine increases are uniquely associated with connectivity patterns that have relevance for the subjective experience of drug reward.


Subject(s)
Brain , Dopamine , Magnetic Resonance Imaging , Methylphenidate , Positron-Emission Tomography , Raclopride , Humans , Male , Adult , Female , Brain/drug effects , Brain/diagnostic imaging , Brain/metabolism , Dopamine/metabolism , Methylphenidate/pharmacology , Methylphenidate/administration & dosage , Double-Blind Method , Young Adult , Raclopride/pharmacology , Central Nervous System Stimulants/pharmacology , Central Nervous System Stimulants/administration & dosage , Receptors, Dopamine D1/metabolism , Neural Pathways/drug effects , Neural Pathways/diagnostic imaging , Dopamine Antagonists/pharmacology , Dopamine Antagonists/administration & dosage , Brain Mapping
2.
Proc Natl Acad Sci U S A ; 120(52): e2314596120, 2023 Dec 26.
Article in English | MEDLINE | ID: mdl-38109535

ABSTRACT

The amplitude of low-frequency fluctuations (ALFF) and global functional connectivity density (gFCD) are fMRI (Functional MRI) metrics widely used to assess resting brain function. However, their differential sensitivity to stimulant-induced dopamine (DA) increases, including the rate of DA rise and the relationship between them, have not been investigated. Here we used, simultaneous PET-fMRI to examine the association between dynamic changes in striatal DA and brain activity as assessed by ALFF and gFCD, following placebo, intravenous (IV), or oral methylphenidate (MP) administration, using a within-subject double-blind placebo-controlled design. In putamen, MP significantly reduced D2/3 receptor availability and strongly reduced ALFF and increased gFCD in the brain for IV-MP (Cohen's d > 1.6) but less so for oral-MP (Cohen's d < 0.6). Enhanced gFCD was associated with both the level and the rate of striatal DA increases, whereas decreased ALFF was only associated with the level of DA increases. These findings suggest distinct representations of neurovascular activation with ALFF and gFCD by stimulant-induced DA increases with differential sensitivity to the rate and the level of DA increases. We also observed an inverse association between gFCD and ALFF that was markedly enhanced during IV-MP, which could reflect an increased contribution from MP's vasoactive properties.


Subject(s)
Brain , Dopamine , Methylphenidate , Brain/diagnostic imaging , Brain/drug effects , Dopamine/pharmacology , Magnetic Resonance Imaging , Methylphenidate/pharmacology , Double-Blind Method
3.
Nat Commun ; 14(1): 6408, 2023 11 08.
Article in English | MEDLINE | ID: mdl-37938560

ABSTRACT

The faster a drug enters the brain, the greater its addictive potential, yet the brain circuits underlying the rate dependency to drug reward remain unresolved. With simultaneous PET-fMRI we linked dynamics of dopamine signaling, brain activity/connectivity, and self-reported 'high' in 20 adults receiving methylphenidate orally (results in slow delivery) and intravenously (results in fast delivery) (trial NCT03326245). We estimated speed of striatal dopamine increases to oral and IV methylphenidate and then tested where brain activity was associated with slow and fast dopamine dynamics (primary endpoint). We then tested whether these brain circuits were temporally associated with individual 'high' ratings to methylphenidate (secondary endpoint). A corticostriatal circuit comprising the dorsal anterior cingulate cortex and insula and their connections with dorsal caudate was activated by fast (but not slow) dopamine increases and paralleled 'high' ratings. These data provide evidence in humans for a link between dACC/insula activation and fast but not slow dopamine increases and document a critical role of the salience network in drug reward.


Subject(s)
Behavior, Addictive , Methylphenidate , Adult , Humans , Brain/diagnostic imaging , Dopamine , Methylphenidate/pharmacology , Reward , Clinical Trials as Topic
4.
Commun Biol ; 6(1): 166, 2023 02 10.
Article in English | MEDLINE | ID: mdl-36765261

ABSTRACT

Dopamine facilitates cognition and is implicated in reward processing. Methylphenidate, a dopamine transporter blocker widely used to treat attention-deficit/hyperactivity disorder, can have rewarding and addictive effects if injected. Since methylphenidate's brain uptake is much faster after intravenous than oral intake, we hypothesize that the speed of dopamine increases in the striatum in addition to its amplitude underly drug reward. To test this we use simulations and PET data of [11C]raclopride's binding displacement with oral and intravenous methylphenidate challenges in 20 healthy controls. Simulations suggest that the time-varying difference in standardized uptake value ratios for [11C]raclopride between placebo and methylphenidate conditions is a proxy for the time-varying dopamine increases induced by methylphenidate. Here we show that the dopamine increase induced by intravenous methylphenidate (0.25 mg/kg) in the striatum is significantly faster than that by oral methylphenidate (60 mg), and its time-to-peak is strongly associated with the intensity of the self-report of "high". We show for the first time that the "high" is associated with the fast dopamine increases induced by methylphenidate.


Subject(s)
Attention Deficit Disorder with Hyperactivity , Methylphenidate , Humans , Methylphenidate/pharmacology , Dopamine/metabolism , Raclopride/metabolism , Raclopride/pharmacology , Raclopride/therapeutic use , Brain/metabolism , Dopamine Antagonists/metabolism , Dopamine Antagonists/pharmacology , Dopamine Antagonists/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...